FDA approves atezolizumab plus chemo for adjuvant Stage III dMMR colon cancer

What happened

The FDA approved atezolizumab (Tecentriq, Genentech) on 8 October 2026, in combination with a fluoropyrimidine and oxaliplatin, as adjuvant treatment for adult and pediatric patients two years and older with Stage III mismatch repair deficient (dMMR) colon cancer after complete resection ^[1]. The clearance sits under Genentech's existing biologic license, BLA 761034 ^[5]. It rests on ATOMIC/ML39057 (NCT02912559), a multicenter, randomized, open-label, active-controlled trial in 711 adults and one pediatric patient whose Stage III dMMR colon cancer had been resected with no residual nodal or metastatic disease ^[1]. Patients were randomized one to one: atezolizumab plus mFOLFOX6 for twelve cycles then atezolizumab alone for six months, against mFOLFOX6 for twelve cycles ^[1]. Disease-free survival was the major efficacy outcome ^[1], and results have been posted to the trial registry ^[2].

Why it matters

The change is the setting, not the molecule. Atezolizumab's established dMMR footprint was unresectable or metastatic disease that had progressed after prior treatment and had no satisfactory alternative, per its current label ^[6]. This approval places the same antibody into curative-intent therapy for resected Stage III patients, on top of standard FOLFOX chemotherapy ^[1]. For a biomarker-selected group, that moves checkpoint blockade from late-line salvage to the adjuvant setting, right after surgery, where cure is still the goal.

It also sharpens a safety question the adjuvant setting weighs differently from metastatic disease. Many resected Stage III patients are already cured by surgery and chemotherapy, so adding an immunotherapy to full FOLFOX puts extra toxicity against a cure some patients already have. The specific adverse-event counts from ATOMIC are not carried in the verified sources Prognyx cites here, so the size of that trade-off stays an open read.

Checkpoint blockade in this biomarker is not itself new to colorectal cancer: the nivolumab plus ipilimumab regimen is already approved in MSI-H/dMMR colorectal cancer ^[7]. What atezolizumab adds is a labeled option in the resected, adjuvant Stage III line specifically ^[1].

What to watch next

Two atezolizumab trials in dMMR colorectal disease are still open and unread. COMMIT (NCT02997228), a Phase 3 NCI study adding atezolizumab in metastatic dMMR colorectal cancer, is active but no longer recruiting, with 120 patients and a primary completion date of 1 June 2027; no results are posted ^[3]. The AIO Phase 2 study (NCT05118724) in high-risk Stage II and Stage III colorectal cancer patients who cannot take oxaliplatin is also active but no longer recruiting, with 80 patients and a primary completion date of April 2027; no results are posted ^[4]. Those readouts would show whether atezolizumab's dMMR story reaches past resected Stage III disease into metastatic and chemo-sparing use.

The now-what

For a team developing checkpoint or combination immunotherapy in colorectal cancer, the resected dMMR adjuvant line now has a labeled competitor, so a rival program needs a clear differentiator: a chemo-free regimen, a distinct dMMR subset such as oxaliplatin-ineligible patients, or a convincing answer to the toxicity-versus-cure question. For partnering, the two pending atezolizumab trials set the calendar: deals signed before the 2027 readouts price in whether this indication widens, deals after them do not. For a group already holding dMMR assets, the near-term task is positioning language and comparator choice, since the adjuvant benchmark has shifted.

What Prognyx could not verify

The specific disease-free and overall survival figures and adverse-event counts from ATOMIC are not in the source text Prognyx could cite; the registry entry confirms only that results are posted ^[2]. No Genentech or Roche press release or SEC filing specific to this dMMR colon cancer approval appears in the public set Prognyx reviewed, and whether the live Tecentriq label text, pricing or launch timing now reflect the indication could not be confirmed from these sources.

Prognyx's read: a moderate, biomarker-bounded competitive move; checkpoint developers in colorectal cancer have until the 2027 readouts (COMMIT, 1 June 2027; AIO, April 2027) to position before atezolizumab's dMMR footprint either widens or stalls.